Reiner Bonnet

View Scopus Profile

Research activity per year

Education/Academic qualification

MD, Loma Linda University

Award Date: May 1 1981

Disciplines

Medicine and Health Sciences

51 Article
3 Review article
2 Conference contribution
1 Meeting abstract

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
KEYNOTE-671 Investigators, Sep 28 2024, In: The Lancet. 404, 10459, p. 1240-1252 13 p.
Research output: Contribution to journal › Article › peer-review

Open Access
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial
RELIEF investigators, May 2021, In: The Lancet Respiratory Medicine. 9, 5, p. 476-486 11 p.
Research output: Contribution to journal › Article › peer-review

Open Access
Positionspapier zur Bedeutung der forcierten Vitalkapazität für Patienten mit idiopathischer Lungenfibrose (IPF)
Translated title of the contribution: Position Paper: Significance of the Forced Vital Capacity in Idiopathic Pulmonary FibrosisBehr, J., Bonella, F., Bonnet, R., Gläser, S., Grohé, C., Günther, A., Koschel, D., Kreuter, M., Kirsten, D., Krögel, C., Markart, P., Müller-Quernheim, J., Neurohr, C., Pfeifer, M., Prasse, A., Schönfeld, N., Schreiber, J., Wirtz, H., Witt, C. & Costabel, U., Aug 12 2015, In: Pneumologie. 69, 8, p. 455-458 4 p.
Research output: Contribution to journal › Article › peer-review

Open Access
50 Jahre WATL (Wissenschaftliche Arbeitsgemeinschaft für die Therapie von Lungenkrankheiten e.V.)
Translated title of the contribution: 50 Years WATL (Scientific Working Group for the Therapy of Lung Diseases)Wirtz, H., Kropp, R., Behr, J., Costabel, U., Bonnet, R., Schönfeld, N., Prasse, A., Kardos, P., Seehausen, V. & Loddenkemper, R., Mar 2014, In: Pneumologie. 68, 3, p. 199-205 7 p.
Research output: Contribution to journal › Review article › peer-review

Open Access
Expektoration von Embolisationsspiralen 15 Jahre nach Embolisation pulmonaler arteriovenöser Malformationen bei hereditärer hämorrhagischer Teleangiektasie (M. Osler-Weber-Rendu)
Translated title of the contribution: Expectoration of embolization coils 15 years after embolization of pulmonary arteriovenous malformations in a patient with hereditary hemorrhagic telangiectasiaSchwarzer, D., Mäder, I., Petrovitch, A., Leonhardi, J. & Bonnet, R., Apr 2014, In: Pneumologie. 68, 4, p. 282-285 4 p.
Research output: Contribution to journal › Article › peer-review

Open Access

Reiner Bonnet, MD

Personal profile

Related documents

Education/Academic qualification

Disciplines

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

Positionspapier zur Bedeutung der forcierten Vitalkapazität für Patienten mit idiopathischer Lungenfibrose (IPF)

50 Jahre WATL (Wissenschaftliche Arbeitsgemeinschaft für die Therapie von Lungenkrankheiten e.V.)

Expektoration von Embolisationsspiralen 15 Jahre nach Embolisation pulmonaler arteriovenöser Malformationen bei hereditärer hämorrhagischer Teleangiektasie (M. Osler-Weber-Rendu)

Reiner Bonnet, MD

Personal profile

Related documents

Education/Academic qualification

Disciplines

Research output

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

Positionspapier zur Bedeutung der forcierten Vitalkapazität für Patienten mit idiopathischer Lungenfibrose (IPF)

50 Jahre WATL (Wissenschaftliche Arbeitsgemeinschaft für die Therapie von Lungenkrankheiten e.V.)

Expektoration von Embolisationsspiralen 15 Jahre nach Embolisation pulmonaler arteriovenöser Malformationen bei hereditärer hämorrhagischer Teleangiektasie (M. Osler-Weber-Rendu)